Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
- 17 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 21 (3), 449-456
- https://doi.org/10.1080/14737167.2021.1880323
Abstract
This study evaluates the cost-effectiveness of pertuzumab with trastuzumab biosimilar and docetaxel as initial treatment for HER2-positive metastatic breast cancer (MBC) in Singapore. A partitioned survival model with three health states was developed to evaluate the cost-effectiveness of trastuzumab biosimilar and docetaxel with or without pertuzumab from a healthcare system perspective over a 15-year time horizon for patients with HER2-positive MBC. Key clinical inputs were derived from the CLEOPATRA trial. Health state utilities were derived from the literature and direct medical costs were obtained from local public healthcare institutions. The base-case resulted in an incremental cost-effectiveness ratio (ICER) of SGD366,658 (USD272,244) per quality-adjusted life-year (QALY) gained. One-way sensitivity analyses showed that the ICER was sensitive to utilities in the progression-free state, price of pertuzumab and time horizon. When the price for trastuzumab reference biologic (branded) was applied, the ICER was even higher (SGD426,996 [USD317,045]/QALY). Although trastuzumab biosimilar reduced the cost of the pertuzumab combination regimen, the ICER remained high and was not cost effective in Singapore’s context. As pertuzumab contributed 80% of the overall combination treatment cost, price reductions for pertuzumab will be required to improve the cost-effectiveness of combination treatment to an acceptable level.Keywords
This publication has 22 references indexed in Scilit:
- Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancerBMC Health Services Research, 2020
- Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancerJournal of Medical Economics, 2020
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studyThe Lancet Oncology, 2020
- Challenges in the value assessment, pricing and funding of targeted combination therapies in oncologyHealth Policy, 2019
- Health Technology Assessment and Its Use in Drug Policies: SingaporeValue in Health Regional Issues, 2019
- Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspectiveBMC Cancer, 2018
- Ten-year survival in women with primary stage IV breast cancerBreast Cancer Research and Treatment, 2016
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerThe New England Journal of Medicine, 2015
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerThe New England Journal of Medicine, 2012